BRAF Mutations In Colorectal Cancer Cause Resistance To Anti-EGFR Therapy, Study Finds
Tuesday, October 28, 2008 - 10:08
in Health & Medicine
European researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with cetuximab and panitumumab. The finding could help doctors better identify which patients are likely to benefit from such treatment, which is commonly used as last-effort therapy but only works in a fraction of patients.
Read the whole article on Science Daily
More from Science Daily
Related
- Cost-effectiveness of cetuximab in metastatic colorectal cancerFri, 7 Aug 2009, 17:30:34 EDT
- Trial of new treatment for advanced melanoma shows rapid shrinking of tumorsWed, 23 Sep 2009, 6:52:34 EDT
- New results help predict treatment response in colorectal cancerTue, 16 Sep 2008, 10:17:53 EDT
- JNCI news brief: Polyclonality of BRAF mutations in acquired melanocytic neviMon, 14 Sep 2009, 18:15:38 EDT
- Gene mutation improves leukemia drug's effectTue, 17 Jun 2008, 14:21:52 EDT